Radiopharm Theranostics Limited (RAD) Stock Statistics & Valuation Metrics

Radiopharm Theranostics Limited has a market cap or net worth of AU$32.98M. The enterprise value is AU$52.25.

Radiopharm Theranostics Limited has 4,710,883,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Radiopharm Theranostics Limited’s return on equity (ROE) is -2.23 and return on invested capital (ROIC) is -165.54%.

The current PE Ratio of Radiopharm Theranostics Limited is ―. Radiopharm Theranostics Limited’s PEG ratio is 0.11.

In the last 12 months, Radiopharm Theranostics Limited had revenue of 2.77M and earned -55.15M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -52.78M and capital expenditures 30.11M, giving a free cash flow of -22.67M billion.

Radiopharm Theranostics Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Radiopharm Theranostics Limited upcoming earnings date is Feb 26, 2027, TBA (Not Confirmed).

Radiopharm Theranostics Limited as a current ratio of 1.16, with Debt / Equity ratio of 0.00%

In the past 12 months, Radiopharm Theranostics Limited has paid -54.44K in taxes.

Radiopharm Theranostics Limited EV to EBITDA ratio is -0.93, with an EV/FCF ratio of 0.00.

Radiopharm Theranostics Limited has AU$4.14M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$4.14M billion.

Gross margin is -39.41%, with operating margin of -2468.61%, and net profit margin of -1992.46%.

The average price target for Radiopharm Theranostics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―